Zenas Biopharma, Common Etf Three Year Return
| ZBIO Etf | USD 11.29 0.71 5.92% |
Zenas BioPharma, Common fundamentals help investors to digest information that contributes to Zenas BioPharma,'s financial success or failures. It also enables traders to predict the movement of Zenas Etf. The fundamental analysis module provides a way to measure Zenas BioPharma,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zenas BioPharma, etf.
Zenas |
Zenas BioPharma, Common ETF Three Year Return Analysis
Zenas BioPharma,'s Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current Zenas BioPharma, Three Year Return | (33.04) % |
Most of Zenas BioPharma,'s fundamental indicators, such as Three Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zenas BioPharma, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Based on the latest financial disclosure, Zenas BioPharma, Common has a Three Year Return of -33.04%. This is much lower than that of the Biotechnology family and significantly lower than that of the Health Care category. The three year return for all United States etfs is notably higher than that of the company.
Zenas Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zenas BioPharma,'s direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Zenas BioPharma, could also be used in its relative valuation, which is a method of valuing Zenas BioPharma, by comparing valuation metrics of similar companies.Zenas BioPharma, is currently under evaluation in three year return as compared to similar ETFs.
Fund Asset Allocation for Zenas BioPharma,
The fund invests most of its assets under management in various types of exotic instruments, with the rest of asset invested in stocks.Asset allocation divides Zenas BioPharma,'s investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Zenas Fundamentals
| EBITDA | (56.31 M) | ||||
| Net Income | (37.12 M) | ||||
| Total Debt | 293.9 M | ||||
| Book Value Per Share | (21.07) X | ||||
| Cash Flow From Operations | (30.53 M) | ||||
| Earnings Per Share | (3.90) X | ||||
| Beta | -2.35 | ||||
| Market Capitalization | 673.29 M | ||||
| Total Asset | 68.18 M | ||||
| Retained Earnings | (230.4 M) | ||||
| Working Capital | 36.55 M | ||||
| One Year Return | (24.31) % | ||||
| Three Year Return | (33.04) % | ||||
| Net Asset | 68.18 M | ||||
| Last Dividend Paid | 0.002 | ||||
| Equity Positions Weight | 20.01 % |
About Zenas BioPharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zenas BioPharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenas BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenas BioPharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against Zenas Etf
| 0.5 | VINC | Vincerx Pharma | PairCorr |
| 0.38 | VCEL | Vericel Corp Ord | PairCorr |
| 0.34 | DTIL | Precision BioSciences | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.